Safety and Preliminary Effectiveness of GLX-100 in Participants With Interstitial Cystitis/Painful Bladder Syndrome.
- Conditions
- Interstitial CystitisPainful Bladder SyndromeRenal and Urogenital - Other renal and urogenital disorders
- Registration Number
- ACTRN12623000602628
- Lead Sponsor
- Glycologix Australia PTY LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
1. Females aged 18 years or greater at the time of signing the informed consent form (ICF);
2. Diagnosis of interstitial cystitis (IC)/ bladder pain syndrome (BPS) according to American Urological Association (AUA) Guidelines 2022 with symptoms for 6 months or more prior to screening;
3. Visual analogue scale (VAS) bladder pain score of at least 4 (average pain during the last 3 days; scale 0 to 10) at Screening and Day 1 (prior to dosing);
4. Had a prior cystoscopy to rule out confounding conditions;
5. Been on unchanged acceptable oral medicines for IC/PBS for at least 3 months prior to Day 1;
6. Positive bladder permeability test during the screening period;
7. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to the first infusion and must not be breastfeeding, lactating or planning pregnancy during the study period. WOCBP must agree to use an acceptable form of contraception during the treatment period and for at least 8 weeks after the last instillation of the investigational medical device;
• WOCBP are defined as any female who has experienced menarche and who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal.
• Menopause is defined as 12 months of amenorrhea in the absence of other biological causes.
8. Be capable of giving informed consent and reading and signing the ICF after the nature of the study has been fully explained by the investigator or investigator designee;
9. Be willing and able to complete all study assessments and procedures and to communicate effectively with the investigator and site staff.
1. Known current Hunner’s lesions;
2. McGill catastrophizing pain score >30;
3. Received narcotics, oral immunosuppressives, pentosan polysulfate, tricyclic antidepressants (TCAs) (e.g., amitriptyline, pregabalin, or nortriptyline), or intravesical treatment for IC/PBS within 1 month, hydrodistension within 3 months, or intradetrusor Botulinum toxin (BOTOX) injections within 12 months prior Day 1;
4. Has untreated endometriosis;
5. Has recurrent urinary tract infection (UTI) (more than 3 UTIs over the last 12 months of the screening visit) or active UTI (positive bacterial urine culture) within 6 weeks prior to Day 1;
6. Have a history of a clinically significant allergic reaction or hypersensitivity, as judged by the investigator, to any drug or any component of the study drug formulations used in the study (see Investigator’s Brochure);
7. Active Coronavirus disease 2019 (COVID-19) infection within 2 weeks prior to Day 1;
8. Active substance abuse (drugs or alcohol), history of chronic substance abuse within the past year, or prior chronic substance abuse judged by the investigator to recur during the study;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and tolerability of GLX-100 by measuring the incidence and severity of adverse events. Examples for possible adverse events include urinary tract infections and urinary urgency that will be assessed according to standard clinical practice. Medical notes will be used to collect adverse event data.[ 16 weeks post initial instillation.]
- Secondary Outcome Measures
Name Time Method Differences in symptoms as measured by Visual Analog Scale[ 16 weeks post initial instillation.];Response to treatment as reflected by a change in baseline measured using Global response scale assessment[ 16 weeks post initial instillation];Change in symptoms as reflected by a change in baseline measured using using Oleary-Sant questionnaire.[ 16 weeks post initial instillation];Change in urinary frequency as reflected by a change in baseline measured using a 24hr urine frequency diary.[ 16 weeks post initial instillation]